With FDA approval, Genentech turns eye implant's focus to diabetes
Genentech Inc. won regulatory approval Tuesday to market an eye implant that can be refilled every six months with an already ...
pharmaphorum6y
Genentech’s Rituxan approved for rare skin disease
Genentech is a member of the Roche Group, with headquarters in California, US. Vertex's gene-editing therapy for sickle cell disease, Casgevy, has been given the nod for use by the NHS in England ...
Nature1y
Cloning and mutagenesis: tinkering with the order of things
Engineering the replication of target DNA through cloning, or changing its genetic code through mutations, are detail-oriented processes whose foibles can spell disaster. Caitlin Smith looks at ...
pharmaphorum8y
Genentech and Hanmi strike $900m cancer deal
Roche’s Genentech unit is to partner with South Korea ... in Q4 this year if it clears US antitrust regulations. Vertex's gene-editing therapy for sickle cell disease, Casgevy, has been ...